In this review we discuss the evolving role of semaglutide, which is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) that has been already approved for the treatment of type II diabetes mellitus (T2DM) and obesity. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.